Mayrhofer, Markus
De Laere, Bram
Whitington, Tom
Van Oyen, Peter
Ghysel, Christophe
Ampe, Jozef
Ost, Piet
Demey, Wim
Hoekx, Lucien
Schrijvers, Dirk
Brouwers, Barbara
Lybaert, Willem
Everaert, Els
De Maeseneer, Daan
Strijbos, Michiel
Bols, Alain
Fransis, Karen
Oeyen, Steffi
van Dam, Pieter-Jan
Van den Eynden, Gert
Rutten, Annemie
Aly, Markus
Nordström, Tobias
Van Laere, Steven
Rantalainen, Mattias
Rajan, Prabhakar
Egevad, Lars
Ullén, Anders
Yachnin, Jeffrey
Dirix, Luc
Grönberg, Henrik
Lindberg, Johan
Funding for this research was provided by:
The Belgian Foundation Against Cancer (C/2014/227)
Kom op tegen Kanker (00000000116000000206)
The Cancer Research Funds of Radiumhemmet, through the PCM program at KI (163012)
The Erling-Persson family foundation (4-2689-2016)
Swedish Research Council (K2010-70X-20430-04-3)
Swedish Cancer Foundation (09-0677)
Article History
Received: 11 May 2018
Accepted: 5 November 2018
First Online: 21 November 2018
Ethics approval and consent to participate
: Ethical approval was obtained from ethical committees in Belgium (Antwerp University Hospital, registration number: B300201524217) and Sweden (Stockholm Regional Ethical Vetting Board registration numbers: 2016/101-32, amendment 2017/252-32; 2009/780-31/4, amendment 2014/1564-32). All patients provided a written informed consent document. The study was conducted in accordance with the Declaration of Helsinki.
: All patients additionally consented to have their data published in an anonymous format. Each patient and blood draw were assigned an untraceable number. The sample donor ID represents a unique patient and the sample ID a specific sampling occasion.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.